(Q24301579)

GOA release 2020-03-11

author name string

J Hong

1

0 references

M V Tejada-Simon

2

0 references

V M Rivera

3

0 references

Y C Q Zang

4

0 references

J Z Zhang

Multiple Sclerosis Journal

5

0 references

language of work or name

English

0 references

publication date

May 2002

0 references

published in

0 references

volume

8

0 references

page(s)

237-42

0 references

issue

3

0 references

cites work

Ubiquitous pathogens: links between infection and autoimmunity in MS?

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Association between clinical disease activity and Epstein-Barr virus reactivation in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Central nervous system complications in human herpesvirus-6 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Plaque-associated expression of human herpesvirus 6 in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

The function of type I interferons in antimicrobial immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

A strongly immunoreactive virion protein of human herpesvirus 6 variant B strain Z29: identification and characterization of the gene and mapping of a variant-specific monoclonal antibody reactive epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

CD46 is a cellular receptor for human herpesvirus 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

More mayhem from molecular mimics

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

Viruses and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

Viruses and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

Interferon beta induces T-helper 2 immune deviation in MS

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021

Human herpesvirus-6: neurologic implications of a newly-described viral pathogen.

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS794OA

7 January 2021